Please ensure Javascript is enabled for purposes of website accessibility

Merck Falling Earnings Hide Hidden Potential

By Dave Williamson and Max Macaluso – Feb 8, 2014 at 7:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Merck has a slight earnings miss, but announces some very exciting partnerships.

In this segment from Market Checkup, Motley Fool's health-care focused investing show, analysts David Williamson and Max Macaluso look at Merck's recent quarterly results. 

The Big Pharma posted declining revenue and net income, missing analyst estimates in the process. However, investors need to dig behind the top-line numbers to get a clear picture of Merck's potential. Guidance for 2014 was not a bad as feared, although it will be a transition year for the company. That doesn't mean the stock is stuck on timeout. Merck's pipeline has a lot of potential, and the company is striking collaboration agreements left and right.

In this video, David and Max dig through the quarterly results and discuss Merck's focus on immuno-oncology, its new partnership deals, and other interesting upcoming pipeline catalysts.

David Williamson owns shares of Merck. Max Macaluso, Ph.D., and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Merck Stock Quote
$110.09 (1.06%) $1.16
Amgen Stock Quote
$285.76 (0.87%) $2.47
Bristol-Myers Squibb Stock Quote
Bristol-Myers Squibb
$79.93 (0.01%) $0.01
Incyte Stock Quote
$84.03 (1.80%) $1.49

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.